Clin Ther. 2007;29(4):617–25.PubMedCrossRef 12. Markowitz JS, Straughn AB, Patrick KS, et al. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet.

2003;42(4):393–401.PubMedCrossRef 13. Biederman J, Melmed RD, Patel A, The SPD503 Study Group, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73–84.PubMedCrossRef find more 14. Sallee F, McGough J, Wigal T, The SPD503 Study Group, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155–65.PubMedCrossRef 15. Biederman J, Melmed RD, Patel A, et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008;13(12):1047–55.PubMed 16. Adler GS-9973 nmr LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009;29(3):239–47.PubMedCrossRef 17. Biederman J, Mick E, Surman

C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829–35.PubMedCrossRef 18. Meyer MC, Straughn AB, Jarvi EJ, et al. Bioequivalence of methylphenidate immediate-release tablets using a replicated buy C59 study design to characterize intrasubject HSP inhibitor clinical trial variability. Pharm Res. 2000;17(4):381–4.PubMedCrossRef 19. Pohl GM, Van Brunt DL, Ye W, et al. A retrospective claims analysis of combination therapy in the treatment

of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Serv Res. 2009;9:95.PubMedCrossRef 20. Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am. 2000;9(3):573–603. viii.PubMed 21. Secnik K, Swensen A, Lage MJ. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder. Pharmacoeconomics. 2005;23(1):93–102.PubMedCrossRef”
“1 Introduction Busulfan (1,4-butanediol dimethanesulphonate) is an alkylating agent used extensively for its anti-tumor properties, characterized in the early 1950s by Galton et al. for the treatment of chronic myeloid leukemia (CML) [1]. Intravenous busulfan was developed to overcome the dosing issues associated with the oral form of the drug (reviewed by Scott et al., 2012 [2]). Currently, busulfan is indicated for use in conjunction with other agents for conditioning prior to hematopoietic stem cell (HSC) transplantation [2, 3].

The data sets supporting the results of this article are available in the GenBank database (Accession numbers XaG1_02: KJ736838 – KJ736944; XaG1_29: KJ736945 – KJ737053; XaG2_52: KJ737163 – KJ737268; XaG1_67: KJ737269 – KJ737369; XaG1_73: KJ737054 – KJ737162) and in the Dryad Digital Repository: http://​doi.​org/​10.​5061/​dryad.​t173v.

Table 1 Characteristics check details of VNTR loci evaluated in Xam isolates from the Colombian Eastern Plains VNTR locus Repeat Number of different alleles Range of allele repetitions Dominant alleles HGDI index G1_02 TCCCCAT 7 1 – 9 4 8 0.7019 G1_29 ATCCCGA 17 1 – 23 5 0.858 G1_52 CCGCCACAACGCA 7 4 – 10 6 0.5873 G1_67 CGACAC 14 10 – 26 16 26 0.8428 G1_73 GGTCAT 8 5 – 12 6 7 9 0.797 VNTR loci were selected according to discriminant index reported by Arrieta and collaborators [36]. Xampopulations presented a genetic differentiation among locations in the Eastern Plains In order to confirm if there

was genetic differentiation among sampled locations, an AMOVA was conducted. ΦPT values showed a statistically significant genetic differentiation Dinaciclib concentration between each pair of locations (Table  2). The differentiation was evidenced using both types of molecular markers. Similar proportions of genetic variation were obtained when comparisons between locations and within locations were performed using AFLPs. However, 80% of the genetic variation was distributed within the sampled locations when isolates were characterized by VNTRs. Furthermore, PCoA analysis showed that AFLPs allowed the detection of a more contrasting differentiation among isolates Danusertib purchase with different geographical origins (Figure 

2). VNTRs also permitted an evident differentiation, but a partial overlapping of isolates from La Libertad and Orocué was observed. However, approximately 75% of the variation among isolates was explained with the first three coordinates of the analysis for both markers (Figure  2). Table 2 Genetic variance among sampled locations in the Eastern Plains using AFLP and VNTR markers Location pair Number of isolates Molecular marker AFLP VNTR Loc. 1 Loc. 2 Loc. 1 Loc. 2 Φ PT LinΦ PT p-value Φ PT LinΦ PT p-value La Libertad Granada 47 3 0.393 0.649 0.001* 0.245 0.324 0.003* La Libertad Orocué 47 50 0.520 1.082 0.001* Thalidomide 0.192 0.238 0.001* Granada Orocué 3 50 0.623 1.649 0.001* 0.196 0.244 0.021* * Statistically significant (p > 0.05). (ΦPT): genetic differentiation among population. (LinΦPT): Linearized genetic differentiation among population. Figure 2 Discrimination of sampled locations in the Colombian Eastern Plains by AFLP and VNTR markers. Disimilarities among Xam isolates were calculated by a Principal Coordinates Analysis (PCoA). Isolates are represented in the PCoA according to their geographical origin. Triangle: La Libertad; square: Granada; rhombus: Orocué. In addition, genetic distances among sampled locations were calculated using the Euclidean distance. A) PCoA was estimated using AFLP data.

With these two selected etching gases, there is a chemical component (from the SiCl4) and a sputter component (mainly Ar). The resulting etching characteristic then depends on the gas mixture and selected powers. Chemical etching of GaAs in the direction is usually two to five times faster than in the perpendicular [0 1 1] direction, therefore increasing the effect of the separated holes. The hole occupation is given with respect to the aspect ratio in Figure 5. For both etching

times, the number of QDs per hole increases with increasing aspect ratio. learn more Compared to the results in Figure 2, this is a bit surprising because the number of QDs per hole decreases with decreasing aspect ratio although the hole diameter is strongly

increasing. Apparently, the tendency of higher occupation numbers for larger holes is influenced by the aspect ratio of the holes. Therefore, it is possible to decrease the occupation by using larger holes with Angiogenesis inhibitor smaller aspect ratios. Figure 5 Influence of the aspect ratio on the hole occupation. The influence of the occupation and diameter of the holes depending on the aspect ratio is given for 10 (a) and 15 s (b) of etching time. With this basic approach of two separated exposure spots, the diameter of the holes increases with decreasing aspect ratio. The advantage of a hole with smaller aspect ratio therefore comes with a disadvantage of a larger hole. Nevertheless, a smaller 4SC-202 price number of QDs per hole nucleate with decreasing aspect ratio but larger hole size. This can be seen for both etching times shown. Increasing the etching time leads to larger holes as Cyclic nucleotide phosphodiesterase seen before, but smaller aspect ratio and thus smaller occupation. At last, the influence of the etching depth is investigated. The etch rate depends strongly on the size of the etched structure, see Figure 3. At first, it increases very strongly with the hole area, which is due to

the supply shortage of the etching gases through the small hole size. With increasing size of the etched structure, this effect becomes negligible and the etch rate converges to the etch rate of a free surface. The largest structures show about an eight times higher etching rate than the smallest investigated structures, which has to be taken into account if structures with different sizes are etched at the same time. The influence of depth on the occupation is investigated next. The 20 s etched holes were too deep for SEM investigation, and therefore, AFM images were used for all samples in Figure 6. The distribution of occupation numbers is shown for three different etching times for an initially equal hole size inside the resist. Figure 6 Influence of depth on the amount of nucleating QDs per holes. In (a), the fraction of the number of QDs per hole nucleating inside a hole is given. With increasing etching duration and therefore depth, the number of QDs per hole decreases.

Krieg AM: Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008,27(2):161–167.PubMedCrossRef 4. Weiner GJ, Liu HM, BMS202 supplier Wooldridge JE, Dahle CE, Krieg AM: Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997,94(20):10833–10837.PubMedCrossRef 5. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM: Human peripheral

blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol 2001,166(4):2372–2377.PubMed 6. Hartmann G, Krieg AM: Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000,164(2):944–953.PubMed 7. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995,374(6522):546–549.PubMedCrossRef 8. Kuo CC, Liang CM, Lai CY, Liang SM: Involvement of heat Selleck Rabusertib shock protein (Hsp) 90 beta but not Hsp90 alpha in antiapoptotic effect of CpG-B oligodeoxynucleotide. J Immunol 2007,178(10):6100–6108.PubMed 9. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, Wagner selleck compound M, Poeck H, Hartmann

E, Jox R, Giese T, Emmerich B, Endres S: B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005,11(4):1490–1499.PubMedCrossRef 10. Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, Blazar BR, Chen W: Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 2010,115(24):5041–5052.PubMedCrossRef 11. Jahrsdorfer B, Jox R, Muhlenhoff L, Tschoep K, Krug A, Rothenfusser S, Meinhardt G, Emmerich B, Endres S, Hartmann G: Modulation of malignant B cell activation and apoptosis

by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 2002,72(1):83–92.PubMed 12. Rubenstein J, Ferreri AJ, Pittaluga S: Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma 2008,49(Suppl 1):43–51.PubMedCrossRef 13. Donnou S, Galand C, Touitou V, Sautes-Fridman C, Fabry Z, Fisson S: Murine models of B-cell lymphomas: promising tools for designing cancer therapies. Adv Hematol 2012, 2012:701–704. 14. Houot R, Levy R: T-cell modulation combined with intratumoral CpG cures lymphoma PTK6 in a mouse model without the need for chemotherapy. Blood 2009,113(15):3546–3552.PubMedCrossRef 15. Weiner GJ: The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol 2000,68(4):455–463.PubMed 16. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R: Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 2007,179(4):2493–2500.PubMed 17. Jahrsdorfer B, Weiner GJ: CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 2008,3(1):27–32.

N Engl J Med 365:1396–1405PubMed 179. Gnant M (2011) Zoledronic acid in Selleck AR-13324 breast cancer: https://www.selleckchem.com/products/cbl0137-cbl-0137.html latest

findings and interpretations. Ther Adv Med Oncol 3:293–301PubMed 180. Zhao X, Xu X, Zhang Q, Jia Z, Sun S, Zhang J, Wang B, Wang Z, Hu X (2011) Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving “metronomic” zoledronic acid. BMC Cancer 11:403PubMed 181. Chlebowski RT, Col N (2011) Bisphosphonates and breast cancer prevention. Anticancer Agents Med Chem 182. Rennert G, Pinchev M, Rennert HS, Gruber SB (2011) Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 29:1146–1150PubMed 183. Sassa S, Okabe H, Nemoto N, Kikuchi H, Kudo H, Sakamoto S (2009) Ibandronate may prevent colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Res 29:4615–4619PubMed 184. XAV-939 in vivo Kahn

MF, Chamot AM (1992) SAPHO syndrome. Rheum Dis Clin North Am 18:225–246PubMed 185. Kopterides P, Pikazis D, Koufos C (2004) Successful treatment of SAPHO syndrome with zoledronic acid. Arthritis Rheum 50:2970–2973PubMed 186. Siau K, Laversuch CJ (2010) SAPHO syndrome in an adult with ulcerative colitis responsive to intravenous pamidronate: a case report and review of the literature. Rheumatol Int 30:1085–1088PubMed 187. Codriansky KA, Runger TM, Bhawan J, Kantarci A, Kissin EY (2008) Multicentric reticulohistiocytosis: a systemic osteoclastic disease? Arthritis Rheum 59:444–448PubMed 188. King MM, Nelson DA (2008) Hypertrophic osteoarthropathy effectively treated with zoledronic acid. Clin Lung Cancer 9:179–182PubMed 189. Schonfeld SE (2010) Strategies for managing periodontal inflammation. J Calif Dent Assoc 38:272–283PubMed PLEKHM2 190. Braithwaite RS, Chlebowski RT, Lau

J, George S, Hess R, Col NF (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18:937–947PubMed 191. Bushnell CD, Goldstein LB (2004) Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology 63:1230–1233PubMed 192. Mosca L, Grady D, Barrett-Connor E et al (2009) Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 40:147–155PubMed 193. Cummings SR, Ensrud K, Delmas PD et al (2010) Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362:686–696PubMed 194. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A (2007) Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272–282PubMed 195. Collins P, Mosca L, Geiger MJ, Grady D, Kornitzer M, Amewou-Atisso MG, Effron MB, Dowsett SA, Barrett-Connor E, Wenger NK (2009) Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors.

Int J Syst Bacteriol 1990,40(2):205–208.PubMedCrossRef 67. Stackebrandt E, Schumann P, Schaal KP, Weiss N: Propionimicrobium gen. nov., a new genus to accommodate Propionibacterium lymphophilum (Torrey 1916) Johnson and Cummins 1972, 1057AL as Propionimicrobium

lymphophilum comb. nov. Int J Syst Evol Microbiol 2002,52(Pt 6):1925–1927.PubMedCrossRef 68. Summanen PH, Durmaz B, Vaisanen ML, Liu C, Molitoris D, Eerola E, Helander IM, Finegold SM: Porphyromonas somerae sp. nov., a pathogen isolated from humans and distinct from porphyromonas levii. J Clin Microbiol 2005,43(9):4455–4459.PubMedCrossRef 69. Human Microbiome Project buy BIBF 1120 catalog [http://​www.​hmpdacc.​org] 70. Human Oral Microbiome Database [http://​www.​homd.​org] 71. European urinalysis guidelines Scand J Clin Lab Invest Suppl 2000, 231:1–86. 72. Butler JE, Young

ND, Lovley DR: Evolution from VX-680 cost a respiratory ancestor to fill syntrophic and fermentative niches: comparative fenomics of six Geobacteraceae species. BMC genomics 2009, 10:103.PubMedCrossRef 73. Dekio I, Hayashi H, Sakamoto M, Kitahara M, Nishikawa T, Suematsu M, Benno Y: Detection of potentially novel bacterial components of the human skin microbiota using culture-independent molecular profiling. J Med Microbiol 2005,54(Pt 12):1231–1238.PubMedCrossRef 74. Gloux K, Berteau O, El Oumami H, Beguet F, Leclerc M, Dore J: A metagenomic beta-glucuronidase uncovers a core adaptive function of the human intestinal microbiome. Proc Natl Acad Sci USA 2011,108(Suppl

Selleckchem TGFbeta inhibitor 1):4539–4546.PubMedCrossRef 75. Haffajee AD, Teles RP, Patel MR, Song X, Veiga N, Socransky SS: Factors affecting Aldehyde dehydrogenase human supragingival biofilm composition. I. Plaque mass. J Periodontal Res 2009,44(4):511–519.PubMedCrossRef 76. Hayashi H, Sakamoto M, Benno Y: Fecal microbial diversity in a strict vegetarian as determined by molecular analysis and cultivation. Microbiol Immunol 2002,46(12):819–831.PubMed 77. Kang JG, Kim SH, Ahn TY: Bacterial diversity in the human saliva from different ages. J Microbiol 2006,44(5):572–576.PubMed 78. Knapp JS, Koumans EH: Neisseria and Branhamella. In Manual of Clinical Microbiology. 7th edition. Edited by: Murray PR, Baron EJ, Pfaller MAea. Washington, DC, USA: ASM press; 1999:586–603. 79. Ling Z, Kong J, Liu F, Zhu H, Chen X, Wang Y, Li L, Nelson KE, Xia Y, Xiang C: Molecular analysis of the diversity of vaginal microbiota associated with bacterial vaginosis. BMC genomics 2010, 11:488.PubMedCrossRef 80. Silva DG, Tinoco EM, Rocha GA, Rocha AM, Guerra JB, Saraiva IE, Queiroz DM: Helicobacter pylori transiently in the mouth may participate in the transmission of infection. Mem Inst Oswaldo Cruz 2010,105(5):657–660.PubMedCrossRef 81. Will C, Thurmer A, Wollherr A, Nacke H, Herold N, Schrumpf M, Gutknecht J, Wubet T, Buscot F, Daniel R: Horizon-specific bacterial community composition of German grassland soils, as revealed by pyrosequencing-based analysis of 16S rRNA genes.

PAO1 again formed the unique BLS but failed to form any biofilm on the plastic surface (data not shown). In contrast, when we repeated the experiment with TSBDC, an iron-deficient medium in which P. aeruginosa grows planktonically and develops conventional biofilm, PAO1 formed a thick mature biofilm attached

to the coverslip surface (data not shown). Figure 1 P. aeruginosa PAO1 forms BLS within the ASM+. After 48 h of growth at 37°C under 20% EO2/static conditions, PAO1/pMRP9-1 developed BLS that were confined to the ASM+ and not attached to the surface of the microtiter plate. The composition of the ASM+ and the bacterial AP26113 purchase inoculation are described in Methods. The gelatinous mass containing the BLS was visualized in situ by CLSM. (A) CLSM micrograph Doramapimod supplier of the PAO1/pMRP9-1 BLS; magnification, 10X; bar, 200.00 nm. (B) 3-D image analysis revealing the architecture of the BLS shown in (A); box, 800.00 pixels (px) W x 600 px H; bar, 100 px. (C) CLSM micrograph of the well bottom after the removal of the gelatinous mass showing no attached bacteria or biofilm (the scattered fluorescence observed is due to autofluorescing debris). Table 1 Effect

of time and environmental variables on PAO1/pMRP9-1 BLS www.selleckchem.com/products/verubecestat.html Variable Image stacks (#) a Total biovolume (μm3/μm2) b Mean thickness (μm) c Roughness coefficient d Total surface area × 107(μm2) e Surface to volume ratio (μm2/μm3) f Time (under 20% EO 2 ) 48 h 10 6.52 ± 0.43 11.6 ± 0.28 0.53 ± 0.02 1.65 ± 0.24 1.54 ± 0.10 72 h 10 11.1 ± 0.40 15.5 ± 0.23 0.18 ± 0.02 2.15 ± 0.03 1.01 ± 0.04 6 d 10 18.2 ± 0.32 17.8 ± 0.06 0.02 ± 0.00 0.96 ± 0.12 0.28 ± 0.04 Mucin concentration (3 d under 20%

EO 2 ) 1X 10 11.1 ± 0.40 15.5 ± 0.23 0.18 ± 0.02 2.15 ± 0.03 1.01 ± 0.04 0.5X 10 13.5 ± 0.24 17.0 ± 0.05 0.08 ± 0.00 2.44 ± .045 0.94 ± 0.03 2X 10 15.4 ± 0.35 17.3 ± 0.08 0.06 ± 0.00 1.97 ± .098 0.67 ± 0.05 DNA concentration (3 ZD1839 d under 20% EO 2 ) 1X 10 11.1 ± 0.40 15.5 ± 0.23 0.18 ± 0.02 2.15 ± 0.03 1.01 ± 0.04 0.5X 10 2.42 ± 0.54 4.37 ± 1.37 1.33 ± 0.20 0.76 ± .220 1.55 ± 0.15 1.5X 10 2.48 ± 0.22 5.52 ± 0.64 1.07 ± 0.07 0.96 ± .086 2.02 ± 0.01 Oxygen concentration (EO 2 ) g 20% 10 11.1 ± 0.40 15.5 ± 0.23 0.18 ± 0.02 2.15 ± 0.03 1.01 ± 0.04 10% 10 19.4 ± 0.28 17.9 ± 0.04 0.01 ± 0.00 0.46 ± 0.12 0.13 ± 0.03 0% 10 0.28 ± 0.19 0.41 ± 0.27 1.94 ± 0.04 0.07 ± 0.06 1.75 ± 0.30 a Each experiment was done in duplicate.

Products from bands were then cloned and PCR amplicons from 10 individual colonies were sequenced. Reliable (> 100 bp) Ruboxistaurin price sequences were obtained for 19 of the 20 TDFs. Each sequence was identified by similarity search using the BLAST program against the GenBank non-redundant check details (nr) public sequence database. As shown in Table 3, 8 transcripts (approximately 42% of selected sequences) showed a significant similarity to sequences with known function, 5 transcripts (26.5% of selected sequences) were closely related to L. casei plasmid sequences, 4 transcripts

(21% of selected sequences) were annotated as hypothetical protein-coding sequences, and 2 transcripts (10.5% of selected sequences) were identified as 5S rRNA. Table 3 Transcript-derived fragments (TDFs) from L. rhamnosus PR1019 over-expressed in CB compared to MRS TDF no Primer combination Length (bp) Biological functiona Organism annotationb Max identity – E-valuec Accession no. Pathway assignmentd COGe KEGG 37 AC/AT 396 Guanylate kinase (EC 2.7.4.8) L. rhamnosus GG 98% – 1e-84 YP_003171760.1 COG0194 [F] ko00230: Purine metabolism 40 AC/AT 302 Putative phosphoketolase (EC 4.1.2.9) L. rhamnosus GG 99% – 3e-57 YP_005864692.1 COG3957 [G] ko00030: Pentose

phosphate pathway 48 AC/AT 199 Monooxygenase L. rhamnosus Lc 705 95% – 6e-17 YP_003174467.1 COG2329: Conserved protein involved in polyketide biosynthesis related to monooxygenase [R] _ 54 AC/AT 137 Hypothetical protein L. rhamnosus 77% – 2e-07 WP_005689523.1 _ _ 72 AC/AT 340 Lipoteichoic acid synthase LtaS Type IIa (EC 3.1.6) L. rhamnosus Lc 705 100% – 5e-43 YP_003173514.1 MM-102 mouse COG1368: Phosphoglycerol transferase and related proteins, alkaline phosphatase superfamily [M] _ 76 AC/AT 433 Conserved hypothetical protein L. rhamnosus Lc 705 85% – 9e-27 YP_003174890.1 _ _ 86 AC/AT 109 L-xylulose 5-phosphate 3-epimerase (EC 5.1.3.22) L. rhamnosus GG 94% – 9e-13 YP_003172471.1 Epothilone B (EPO906, Patupilone) COG3623 [G] ko00040:

Pentose and glucuronate interconversions 93 AC/AT 305 Pyruvate oxidase (EC 1.2.3.3) L. rhamnosus GG 93% – 5e-40 YP_003171582.1 COG3961: Pyruvate decarboxylase and related thiamine pyrophosphate-requiring enzymes [G] ko00620: Pyruvate metabolism 95 AC/AT 229 Plasmid pNCD0151 L. casei 98% – 4e-68 Z50861.1 _ _ 97 AC/AT 227 Plasmid pNCD0151 L. casei 96% – 3e-64 Z50861.1 _ _ 106 AC/AT 170 Plasmid pNCD0151 L. casei 97% – 9e-48 Z50861.1 _ _ 120 AC/AT 107 Hypothetical protein L. casei 96% – 4e-10 WP_003574536.1 _ _ 121 AC/AT 105 Imidazoleglycerol-phosphate dehydratase (EC 4.2.1.19) L. rhamnosus Lc 705 92% – 5e-08 YP_003174148.1 COG0131 [E] ko00340: Hystidine metabolism 122 AC/AT 102 Plasmid pNCD0151 L. casei 96% – 5e-23 Z50861.1 _ _ 162 AT/AC 350 Calcineurin-like phosphoesterase family protein L. rhamnosus ATCC 8530 97% – 3e-70 YP_005872999.1 COG0737: 5′-nucleotidase/2′,3′-cyclic phosphodiesterase and related esterases [F] _ 168 AT/AC 238 Plasmid pNCD0151 L. casei 98% – 1e-68 Z50861.

Nano Lett 2007, 7:1013–1017.CrossRef 7. Pinkhasova P, Yang L, Zhang Y, Sukhishvili S, Du H: Differential SERS activity of gold and silver nanostructures enabled by adsorbed poly(vinylpyrrolidone). Langmuir 2012, 28:2529–2535.CrossRef 8. Kong X, Yu Q, Zhang X, Du X, Gong H, Jiang H: Synthesis

and application of Temsirolimus mouse surface-enhanced Raman scattering (SERS) tags of Ag@SiO 2 core/shell nanoparticles in protein detection. J Mater Chem 2012, 22:7767–7774.CrossRef 9. Stoddart Selleckchem mTOR inhibitor PR, Cadusch PJ, Boyce TM, Erasmus RM, Comins JD: Optical properties of chitin: surface-enhanced Raman scattering substrates based on antireflection structures on cicada wings. Nanotechnology 2006, 17:680–686.CrossRef 10. Tan Y, Zang X, Gu J, Liu D, Zhu S, Su H, Feng C, Liu Q, Lau WM, Moon WJ, Zhang D: Morphological effects on surface-enhanced Raman scattering from silver butterfly wing scales synthesized via photoreduction. Langmuir 2011, 27:11742–11746.CrossRef 11. Kumar GVP: Gold nanoparticle-coated biomaterial as SERS micro-probes. Bull Mater Sci 2011, 34:417–422.CrossRef 12. Tan Y, Gu J, Zang X, Xu W, Shi K, Xu L, Zhang D: Versatile fabrication of intact three-dimensional metallic butterfly wing scales with hierarchical sub-micrometer structures. Angew Chem Int Ed 2011, 50:8307–8311.CrossRef 13. Tan Y, Gu J, Xu L, Zang X, Liu D, Zhang W, Liu Q, Zhu S, Su H, Feng C, Fan G, Zhang MM-102 research buy D: High-density hotspots

engineered naturally piled-up subwavelength structures in three dimensional copper butterfly wing scales for surface-enhanced Raman scattering detection. Adv Funct Mater Ed 2012, 22:1578–1585.CrossRef 14. Jiwei Q, Yudong L, Ming Y, Qiang W, Zongqiang C, Wudeng W, Wenqiang L, Xuanyi Y, Jingjun X, Qian S: Large-area Thalidomide high-performance SERS substrates with deep controllable sub-10-nm gap structure fabricated by depositing Au film on the cicada wing. Nanoscale Res Lett 2013, 8:437–442.CrossRef 15. Wilson SJ, Hutley MC: The optical properties of ‘moth eye’ antireflection surfaces. Opt Acta 1982, 29:993–1009.CrossRef 16. Huang J, Wang X,

Wang ZL: Controlled replication of butterfly wings for achieving tunable photonic properties. Nano Lett 2006, 6:2325–2331.CrossRef 17. Tanahashi I: Photocatalytic preparation of Ag/TiO 2 films and their localized surface plasmon resonance sensing properties. Bull Chem Soc Jpn 2007, 80:2019–2023.CrossRef 18. Tanahashi I, Iwagishi H, Chang G: Localized surface plasmon resonance sensing properties of photocatalytically prepared Au/TiO 2 films. Mater Lett 2008, 62:2714–2716.CrossRef 19. Lu Y, Liu GL, Lee LP: High-density silver nanoparticle film with temperature-controllable interparticle spacing for a tunable surface enhanced Raman scattering substrate. Nano Lett 2005, 5:5–9.CrossRef Competing interests The authors declare that they have no competing interests.

Methods

In this work, the fabrication of the self-assembled Au droplets was investigated on various GaAs type-B (n11) substrates, where n is 9, 8, 7, 5, 4, and 2 in a pulsed laser deposition (PLD) system. The GaAs wafers utilized in this work were semi-insulating or undoped with an off-axis of ±0.1° from this website the Wafer Technology Ltd. (Milton Keynes, UK). To start with, a batch of samples including the various type-B GaAs substrates was indium soldered on an Inconel sample holder side by side to maintain the uniformity among the samples and then was treated with a 30-min degas process at 350°C under 1 × 10-4 Torr to remove the contaminants. Subsequently, Au deposition was equally performed on the various type-B GaAs substrates

at a growth rate of 0.05 nm/s with an ionization current of 3 mA under 1 × 10-1 Torr in P505-15 nmr a plasma ion-coater chamber. Au deposition of 2, 3, 4, 6, 9, and 12 nm was systematically performed, and regardless of the deposition amount, the surface showed a quite smooth morphology as shown in Figure 1b,b-1. As an example, Table 1 shows the root-mean-square (RMS) roughness (R q) of the various GaAs surfaces after the 3-nm Au deposition as compared to the Figure 1b. Next, annealing process was implemented by a programmed recipe, and the substrate temperature (T sub) was gradually increased to 550°C from the ambient temperature (Quisinostat approximately 25°C) at a fixed rate of 1.83°C/s under a chamber pressure of 1 × 10-4 Torr. After reaching the target T sub (550°C) [35], the samples were Depsipeptide molecular weight dwelt for 150 s to ensure the maturation of the droplets. Immediately after the dwell process, the samples were quenched down to the ambient temperature to minimize the ripening effect [36, 37]. An atomic force microscope (AFM) under atmospheric pressure was employed to characterize the surface morphology

with non-contact tapping mode. The tips used in this work were NSC16/AIBS (μmasch, Lady’s Island, SC, USA) with a curvature radius less than 10 nm. The spring constant was approximately 40 N/m, and the resonation frequency was approximately 170 kHz. A scanning electron microscope (SEM) under vacuum was utilized for the characterizations of the resulting samples, and energy-dispersive X-ray spectrometry (EDS) was utilized (Thermo Fisher Noran System 7, Thermo Fisher Scientific, Waltham, MA, USA) for the elemental analysis. Table 1 Root-mean-square (RMS) roughness ( R q ) of various GaAs surfaces after 3-nm Au deposition Surface (211)B (411)B (511)B (711)B (811)B (911)B R q [nm] 0.361 0.264 0.232 0.351 0.347 0.269 Results and discussion Figure 2 shows the self-assembled Au droplets on GaAs (211)B by the systematic variation of the Au DA from 2 to 12 nm with subsequent annealing at 550°C. Figure labels indicate the related DAs. AFM top views (3 × 3 μm2) of the corresponding samples are shown in Figure 2a,b,c,d,e,f along with enlarged 1 × 1 μm2 images below.